大会日程（7月16日第二天）
PROGRAM FOR BEST OF ASCO IN CHINA 2011（DAY 2）
| July 16, 2011 Day 2 | ||
| Time | Session | Speaker |
| 8:00–8:10 | Welcome to day 2 | 吴一龙(Yilong Wu) |
| Lung Cancer Session 1 Chair: 莫树锦(Tony Mok) | ||
| 8:10–8:35 | 7506 Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: The NCI’s lung cancer mutation consortium (LCMC). | 陆 舜(Shun Lu) |
| 7505 Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. An international, randomized, placebo–controlled, double–blind phase 3 study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). | ||
| LBA7512 An international randomized, placebo–control, double–blind phase 3 study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced mnonsquamous non–small–cell lung cancer (NSCLC). | ||
| 8:35–8:50 | Discussion Topic: Where we are heading with targeted therapy in lung cancer? | Ken O’Byrne 翻译：郭 晔(Ye Guo) |
| 8:50–8:55 | Q & A | 莫树锦(Tony Mok), Ken O’Byrne 陆 舜(Shun Lu) |
| Lung Cancer Session 2 Chair: 陆 舜(Shun Lu) | ||
| 8:55–9:15 | LBA7511 Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non–small–cell lung cancer (NSCLC) in China (INFORM) (C–TOMG 0804). | 张 力(Li Zhang) |
| 7004 Evaluation of disease–free survival as surrogate endpoint for overall survival using two individual patient data meta–analyses of adjuvant chemotherapy in operable non–small cell lung cancer. | ||
| 9:15–9:25 | Discussion Topic: What is the appropriate endpoint for adjuvant and maintenance studies of NSCLC ? | 吴一龙 (Yilong Wu) |
| 9:25–9:30 | Q & A | 陆 舜(Shun Lu) 吴一龙 (Yilong Wu) 张 力(Li Zhang) |
| Lung Cancer Session 3 Chair: 吴一龙 (Yilong Wu) | ||
| 9:30–10:00 | 7503 Erlotinib vs chemotherapy (CT in advanced non–small–cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Tarceva vs chemotherapy (EURTAC) phase III randomized trial. | 莫树锦(Tony Mok) |
| 7510 PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced non–squamous non–small cell lung cancer (NSCLC). | ||
| 7003 Proteomic analysis for detection of NSCLC: Results of ACOSOG Z4031. | ||
| 10:00–10:10 | Discussion Topic: The current standard first line therapy of advanced NSCLC | 程 颖 (Ying Cheng) |
| 10:10–10:15 | Q & A | 吴一龙(Yilong Wu) 莫树锦(Tony Mok) 程 颖 (Ying Cheng) |
| 10:15–10:25 | Break | |
| Breast Cancer Session 1 Chair: 于 丁(Ding Yu) | ||
| 10:25–10:50 | 505 TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2–overexpressin breast cancer. | 江泽飞(Zefei Jiang) |
| 509 LANDSCAPE: A FNCLCC phase II study with lapatinib (L) and capecitabine © in patients with brain metastases (BM) form HER2–positive (+) metastatic breast cancer (MBC) before whole brain radiotherapy (WBR). | ||
| 506 Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. | ||
| 10:50–11:05 | Discussion Topic: The role of lapatinib in management of HER2+ breast cancer? | Maureen Trudeau 翻译: 樊 英(Ying Fan) |
| 11:05–11:10 | Q & A | 于 丁(Ding Yu), Maureen Trudeau, 江泽飞(Zefei Jiang) |
| Breast Cancer Session 2 Chair: 江泽飞(Zefei Jiang) | ||
| 11:10–11:35 | 1004 First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high risk early breast cancer. | 张清媛(Qingyuan Zhang) |
| 1007 A randomized phase III study of iniparib (BSI–201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple–negative breast cancer (TNBC). | ||
| LBA1005 The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B–40. | ||
| 11:35–11:45 | Discussion Topic: Management of triple negative breast cancer | 徐兵河(Binghe Xu) |
| 11:45–11:50 | Q & A | 江泽飞(Zefei Jiang), 徐兵河(Binghe Xu), 张清媛(Qingyuan Zhang) |
| 11:50–14:00 | Lunch and/or satellite symposium | |
| Breast Cancer Session 3 Chair: 徐兵河(Binghe Xu) | ||
| 14:00–14:20 | LBA504 NCIC CTG MAP 3: a phase III placebo–controlled Breast Cancer Prevention Trial of exemestane in postmenopausal women at risk for breast. | |
| 1000 Genetic associations with taxane–induced neuropathy by genome–wide association study (GWAS) in E5103. | ||
| 14:20–14:30 | Discussion Topic: Can we prevent breast cancer? | 于 丁(Ding Yu) |
| 14:30–14:35 | Q & A | 徐兵河(Binghe Xu) 于 丁(Ding Yu) 陆劲松(Jinsong Lu) |
| Sarcoma Session Chair: 牛晓辉(Xiaohui Niu) | ||
| 14:35–14:55 | 10005 Results of the phase 3, placebo–controlled trial (SUCEED) evaluating the mTOR inhibitor ridaforolimus ® as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). | 王 洁(Jie Wang) |
| LBA10002 PALETTE: A randomized double blind phase III trail of pazopanib versus placebo in patients with soft tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy, an EORTC STBSG global network study (EORTC 62072). | ||
| 14:55–15:05 | Discussion Topic: Targeted therapy for sarcoma? | 徐兵河(Binghe Xu) |
| 15:05–15:10 | Q & A | 牛晓辉(Xiaohui Niu) 徐兵河(Binghe Xu) 王 洁(Jie Wang) |
| 15:10–15:20 | Break | |
| Current Standard Practice after ASCO 2011 Chair: 王绿化(Luhua Wang) | ||
| 15:20–16:00 | Target therapy progression of Breast Cancer | Maureen Trudeau 翻译: 樊 英(Ying Fan) |
| 16:00–16:30 | Chemotherapy progression of Breast Cancer | 江泽飞(Zefei Jiang) |
| 16:30–17:10 | Target therapy progression of NSCLC | Ken O’Byrne 翻译：郭 晔(Ye Guo) |
| 17:10–17:40 | Chemotherapy progression of NSCLC | 吴一龙 (Yilong Wu) |
| 17:40–17:45 | Closing remark | 秦叔逵(Shukui Qin) |
| 17:45–19:30 | Buffet Dinner | |
编辑: riset 作者:丁香园通讯员
以下网友留言只代表网友个人观点，不代表网站观点
